Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Relative benefits and risks of diclofenac

From: Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis

  Outcome Unit Assessment time point Placebo Celecoxib Naproxen Etoricoxib Ibuprofen Acetaminophen
Benefits Pain (VAS) ΔCFB (mm) 6 weeks −13.5 (−16.7, −10.4) −4.7 (−8.0, −1.4) −3.4 (−7.0, 0.1) −0.1 (−4.3, 4.0) −3.2 (−7.9, 1.5) −9.1 (−13.5, −4.7)
ΔCFB (mm) 12 weeks −12.3 (−17.3, −7.4) −5.1 (−10.2, −0.1) −3.3 (−8.6, 1.8) −3.3 (−9.1, 2.5) −4.5 (−11.5, 2.4) −8.0 (−16.6, 0.5)
Physical functioning (VAS) ΔCFB (mm) 6 weeks −7.7 (−11.9, −3.4) 0.2 (−4.1, 4.6) 2.8 (−1.7, 7.4) 2.4 (−2.4, 7.3) 1.2 (−4.5, 6.9) −5.4 (−12.4, 1.8)
ΔCFB (mm) 12 weeks −4.5 (−12.4, 3.1) 2.3 (−5.7, 10.5) 6.0 (−2.2, 14.1) 5.8 (−2.9, 14.3) 3.3 (−5.9, 12.3) −7.2 (−14.5, 0.3)
PGA VAS ΔCFB (mm) 6 weeks −15.3 (−25.4, −5.2) −5.7 (−16.1, 4.7) −6.3 (−17.1, 4.5) −5.9 (−18.0, 6.0) −3.7 (−14.7, 7.4) NA
Risks APTC Rate ratio Duration of study NA 1.1 (0.7, 1.8) 0.9 (0.4, 2.0) 1.0 (0.9, 1.2) 0.9 (0.5, 1.6) NA
Major CV event Rate ratio Duration of study NA 1.2 (0.8, 1.8) 0.9 (0.4, 1.9) 1.1 (0.9, 1.3) 1.1 (0.7, 1.9) NA
Major GI event Rate ratio Duration of study NA 1.4 (0.8, 2.3) 0.3 (0.2, 0.6) 1.5 (1.3, 1.9) 0.5 (0.3, 0.9) NA
Withdrawal due to any reason Rate ratio Duration of study 0.7 (0.6, 0.8) 1.1 (1.0, 1.3) 1.0 (0.8, 1.2) 1.2 (1.0, 1.5) 0.7 (0.6, 0.9) 0.8 (0.6, 1.0)
Withdrawal due to adverse events Rate ratio Duration of study 1.6 (1.3, 1.9) 1.4 (1.2, 1.8) 1.1 (0.9, 1.4) 1.7 (1.3, 2.2) 0.9 (0.7, 1.2) 0.9 (0.6, 1.4)
Withdrawal due to lack of efficacy Rate ratio Duration of study 0.4 (0.3, 0.4) 0.8 (0.7, 1.0) 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 0.7 (0.5, 0.9) 0.6 (0.4, 0.8)
  1. Mean and 95% credible intervals are presented; negative ∆CFB and rate ratios <1 favour diclofenac. Benefits were assessed using diclofenac 150 mg/day, naproxen 1,000 mg/day, ibuprofen 2,400 mg/day, celecoxib 200 mg/day, and etoricoxib 60 mg/day. Risks were assessed using dose ranges of the interventions of interest (diclofenac 75 to 200 mg/day, naproxen 500 to 1,500 mg/day, ibuprofen 1,200 to 2,400 mg/day, celecoxib 100 to 800 mg/day, or etoricoxib 30 to 90 mg/day). VAS, visual analogue scale; ΔCFB, difference in change from baseline; PGA, patient global assessment; APTC, Antiplatelets Trialists’ Collaboration; CV, cardiovascular; GI, gastrointestinal.